Apellis Pharmaceuticals

Apellis shares rose to $40.87, marking a 52-week high; market capitalization is around $5.2 billion. Biogen announced the takeover, offering $41 per share in cash plus conditional value rights that could raise the price by up to $4, making the initial equity value about $5.6 billion. Analysts adjusted their ratings after the announcement, while valuation metrics—such as a P/E ratio of 237 and an overbought RSI—point to possible overvaluation. Despite roughly $1 billion in revenue in the past twelve months, Apellis is still unlikely to be profitable; the transaction is expected to close in Q2 2026. » Mere på de.investing.com

Biogen is offering $5.6 billion for Apellis, paying $41 per share plus potential milestone payments related to Syfovre. The bid includes a hefty premium of 86% to the volume-weighted 90-day average price and 35% to the 52-week high. After the deal, Apellis shares rise nearly 140% in premarket trading; Biogen is likely primarily targeting Syfovre and the pegcetacoplan program. » Mere på deraktionaer.de

Apellis described 2025 as a transition year and expects accelerated revenue growth in 2026, supported by the launches of SYFOVRE and EMPAVELI. SYFOVRE showed a stable market position but is being hampered by disruptions in co‑pay programs, while EMPAVELI is off to a stronger‑than‑expected start in C3G/IC‑MPGN. The company closed 2025 with $466 million in cash and expects to have over $500 million in Q1 2026; a $94 million convertible bond maturing in September is planned to be serviced. The pipeline includes gene‑editing programs, FcRn programs and combination studies with a goal of reaching profitability. » Mere på de.investing.com